在急性至慢性肝衰竭患者中开发并首次临床使用体外人工多器官系统
Suhail Ahmad1, Alexander Novokhodko2, Iris W Liou1
1From the Department of Medicine, University of Washington, Seattle, Washington.
概括
一种新的人工多器官置换系统 (AMOR) 有效治疗急性至慢性肝衰竭 (AOCLF) 患者的多器官衰竭 (MOF). 艾莫尔可以去除毒素和多余的液体,改善患者的健康状况,支持重要器官的功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 肝病学 肝病学是一种肝病学.
- 关键护理医学 关键护理医学
背景情况:
- 多器官衰竭 (MOF) 具有显著的死亡风险,特别是在急性至慢性肝衰竭 (AOCLF) 患者中.
- 标准血液透析在MOF患者中通常是无效的,原因是心血管不稳定和流体过载.
- 现有的体外支持系统在将患者连接到肝移植时存在局限性.
研究的目的:
- 评估一种新型人工多器官替代系统 (AMOR) 的疗效和安全性,用于治疗AOCLF患者的MOF.
- 评估AMOR消除与蛋白质结合的毒素和管理液体过载的能力.
- 确定AMOR对患者生存和器官功能恢复的影响.
主要方法:
- 开发人工多器官替代系统 (AMOR),结合白蛋白透析,木炭吸附剂和血液透析.
- 使用AMOR系统治疗10名患有三种或以上器官衰竭的AOCLF患者.
- 监测临床改善,液体清除,毒素清除和患者的治疗结果.
主要成果:
- 所有十名患者在AMOR治疗后都显示出显著的临床改善.
- 艾莫尔成功地清除了大量的多余体液,克服了传统血液透析的局限性.
- 在接受治疗的队列中,有50%的患者接受了肝移植或实现了自发性肝功能恢复.
- 在这项试点研究中,AMOR系统被证明是具有成本效益和用户友好的.
结论:
- 人工多器官替代系统 (AMOR) 是对AOCLF患者多器官衰竭的有效治疗方法.
- 艾莫尔能够管理液体过载和去除毒素,支持重要器官功能,并改善患者的预后.
- 需要对AMOR进行进一步的研究,以确定它在治疗MOF.重症患者中的作用.
相关概念视频
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...


